Painkiller-Sparing nerve block trial pulled before it began
NCT ID NCT04655339
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study planned to test a laparoscopic-guided nerve block (TAP block) to reduce opioid painkiller use after weight-loss or anti-reflux stomach surgeries. It compared two numbing medicines, Bupivacaine HCL and Exparel. However, the trial was withdrawn before enrolling any participants, so no data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Liposomal Bupivacaine (Exparel) and Bupivacaine HCL
- What this could lead to
- If it had worked, this could point toward a way to reduce opioid painkiller use after certain stomach surgeries.
- What could go wrong
- The trial was withdrawn before it started, so no results are available. It is unclear if the approach is effective or safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACHALASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Baylor University Medical Center
Dallas, Texas, 75246, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can a 5-Pill opioid prescription match a 30-Pill one after hip surgery?